Chester Yuan
Publications by Year
Research Areas
Hormonal Regulation and Hypertension, Pharmacogenetics and Drug Metabolism, Estrogen and related hormone effects, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography
Most-Cited Works
- → Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)(2016)81 cited
- → Discovery of TRPM8 Antagonist (S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine(2018)61 cited
- → 2-(S)-Phenethylaminothiazolones as Potent, Orally Efficacious Inhibitors of 11β-Hydroxysteriod Dehydrogenase Type 1(2007)50 cited
- → The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors(2007)41 cited
- → Cytochrome P450-Mediated Epoxidation of 2-Aminothiazole-Based AKT Inhibitors: Identification of Novel GSH Adducts and Reduction of Metabolic Activation through Structural Changes Guided by in Silico and in Vitro Screening(2010)30 cited
- → Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer’s disease(2015)30 cited
- → Further Studies with the 2-Amino-1,3-thiazol-4(5H)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic Model(2008)28 cited
- → Potent Nonpeptide Antagonists of the Bradykinin B1 Receptor: Structure−Activity Relationship Studies with Novel Diaminochroman Carboxamides(2007)26 cited
- → Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes(2011)21 cited
- → Azole-based inhibitors of AKT/PKB for the treatment of cancer(2010)17 cited